The role of ex-situ perfusion for thoracic organs.
Journal
Current opinion in organ transplantation
ISSN: 1531-7013
Titre abrégé: Curr Opin Organ Transplant
Pays: United States
ID NLM: 9717388
Informations de publication
Date de publication:
01 10 2022
01 10 2022
Historique:
pubmed:
12
8
2022
medline:
16
9
2022
entrez:
11
8
2022
Statut:
ppublish
Résumé
Ex-situ machine perfusion for both heart (HTx) and lung transplantation (LuTx) reduces ischemia-reperfusion injury (IRI), allows for greater flexibility in geographical donor management, continuous monitoring, organ assessment for extended evaluation, and potential reconditioning of marginal organs. In this review, we will delineate the impact of machine perfusion, characterize novel opportunities, and outline potential challenges lying ahead to improve further implementation. Due to the success of several randomized controlled trials (RCT), comparing cold storage to machine perfusion in HTx and LuTx, implementation and innovation continues. Indeed, it represents a promising interface for organ-specific therapies targeting IRI, allo-immune responses, and graft reconditioning. These mostly experimental efforts range from genetic approaches and nanotechnology to cellular therapies, involving mesenchymal stem cell application. Despite tremendous potential, prior to clinical transition, more data is needed. Collectively, machine perfusion constitutes the vanguard in thoracic organ transplantation research with extensive potential for expanding the donor pool, enhancing transplant outcomes as well as developing novel therapy approaches.
Identifiants
pubmed: 35950888
doi: 10.1097/MOT.0000000000001008
pii: 00075200-202210000-00015
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
466-473Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Weill D. Lung transplantation: indications and contraindications. J Thorac Dis 2018; 10:4574–4587.
Alraies MC, Eckman P. Adult heart transplant: indications and outcomes. J Thorac Dis 2014; 6:1120–1128.
Valapour M, Lehr CJ, Skeans MA, et al. OPTN/SRTR 2020 Annual Data Report: lung. Am J Transplant 2022; 22: (Suppl 2): 438–518.
Colvin M, Smith JM, Ahn Y, et al. OPTN/SRTR 2020 Annual Data Report: heart. Am J Transplant 2022; 22: (Suppl 2): 350–437.
Pinezich M, Vunjak-Novakovic G. Bioengineering approaches to organ preservation ex vivo. Exp Biol Med (Maywood) 2019; 244:630–645.
Steen S, Sjöberg T, Pierre L, et al. Transplantation of lungs from a nonheart-beating donor. Lancet 2001; 357:825–829.
Qin G, Jernryd V, Sjöberg T, et al. Machine perfusion for human heart preservation: a systematic review. Transpl Int 2022; 35:10258.
Chen-Yoshikawa TF. Ischemia-reperfusion injury in lung transplantation. Cells 2021; 10:1333.
Iske J, Hinze CA, Salman J, et al. The potential of ex vivo lung perfusion on improving organ quality and ameliorating ischemia reperfusion injury. Am J Transplant 2021; 21:3831–3839.
Karimian N, Yeh H. Opportunities for therapeutic intervention during machine perfusion. Curr Transplant Rep 2017; 4:141–148.
Barnard CN. The operation. A human cardiac transplant: an interim report of a successful operation performed at Groote Schuur Hospital, Cape Town. S Afr Med J 1967; 41:1271–1274.
Rajab TK, Singh SK. Donation after cardiac death heart transplantation in America is clinically necessary and ethically justified. Circ Heart Fail 2018; 11:e004884.
Sánchez-Cámara S, Asensio-López MC, Royo-Villanova M, et al. Critical warm ischemia time point for cardiac donation after circulatory death. Am J Transplant 2022; 22:1321–1328.
Lund LH, Khush KK, Cherikh WS, et al. International Society for Heart and Lung Transplantation. The Registry of the International Society for Heart and Lung Transplantation: Thirty-fourth Adult Heart Transplantation Report-2017; Focus Theme: allograft ischemic time. J Heart Lung Transplant 2017; 36:1037–1046.
Valero-Masa MJ, González-Vílchez F, Almenar-Bonet L, et al. Cold ischemia >4 h increases heart transplantation mortality. An analysis of the Spanish heart transplantation registry. Int J Cardiol 2020; 319:14–19.
Khoshbin E, Schueler S. Pretransplant ventricular assist device explant. Ann Cardiothorac Surg 2018; 7:160–168.
Schraufnagel DP, Steffen RJ, Vargo PR, et al. Devices for ex vivo heart and lung perfusion. Expert Rev Med Devices 2018; 15:183–191.
Lu J, Xu L, Zeng Z, et al. Normothermic ex vivo heart perfusion combined with melatonin enhances myocardial protection in rat donation after circulatory death hearts via inhibiting NLRP3 inflammasome-mediated pyroptosis. Front Cell Dev Biol 2021; 9:733183.
Falk C, Ius F, Rojas-Hernandez SV, et al. Effects of ex vivo perfusion and IL-6 receptor blockade on ischemia reperfusion injury in cardiac transplantation. J Heart Lung Transplant 2019; 38:S240.
Critchley WR, Stone JP, Liao Q, et al. Nonischemic Heart preservation via hypothermic cardioplegic perfusion induces immunodepletion of donor hearts resulting in diminished graft infiltration following transplantation. Front Immunol 2020; 11:1621.
Hassanein WH, Zellos L, Tyrrell TA, et al. Continuous perfusion of donor hearts in the beating state extends preservation time and improves recovery of function. J Thorac Cardiovasc Surg 1998; 116:821–830.
Tenderich G, Tsui S, El-Banayosy A, et al. 293: the 1-year follow-up results of the PROTECT patient population using the organ care system. J Heart Lung Transplant 2008; 27:S166.
Messer S, Ardehali A, Tsui S. Normothermic donor heart perfusion: current clinical experience and the future. Transpl Int 2015; 28:634–642.
Ardehali A, Esmailian F, Deng M, et al. Ex-vivo perfusion of donor hearts for human heart transplantation (PROCEED II): a prospective, open-label, multicentre, randomised noninferiority trial. Lancet 2015; 385:2577–2584.
Chan JL, Kobashigawa JA, Reich HJ, et al. Intermediate outcomes with ex-vivo allograft perfusion for heart transplantation. J Heart Lung Transplant 2017; 36:258–263.
Schroder JN, D’Alessandro D, Esmailian F, et al. Successful Utilization of Extended Criteria Donor (ECD) Hearts for transplantation - results of the OCS™ HEART EXPAND Trial to evaluate the effectiveness and safety of the OCS heart system to preserve and assess ECD hearts for transplantation. J Heart Lung Transplant 2019; 38:S42.
Stamp NL, Shah A, Vincent V, et al. Successful heart transplant after ten hours out-of-body time using the TransMedics Organ Care System. Heart Lung Circ 2015; 24:611–613.
Hassanein AH, Elbatanony A, Abdelaziem A, Solomon SD. 241: The Organ Care System (OCS) enables ex-vivo assessment of donor heart coronary perfusion using contrast echocardiography. J Heart Lung Transplant 2009; 28:S150.
Stone JP, Ball AL, Crichley W, et al. Ex vivo lung perfusion improves the inflammatory signaling profile of the porcine donor lung following transplantation. Transplantation 2020; 104:1899–1905.
Andreasson AS, Karamanou DM, Gillespie CS, et al. Profiling inflammation and tissue injury markers in perfusate and bronchoalveolar lavage fluid during human ex vivo lung perfusion. Eur J Cardiothorac Surg 2017; 51:577–586.
Dromparis P, Aboelnazar NS, Wagner S, et al. Ex vivo perfusion induces a time- and perfusate-dependent molecular repair response in explanted porcine lungs. Am J Transplant 2019; 19:1024–1036.
Yeung JC, Zamel R, Klement W, et al. Towards donor lung recovery-gene expression changes during ex vivo lung perfusion of human lungs. Am J Transplant 2018; 18:1518–1526.
Nakajima D, Date H. Ex vivo lung perfusion in lung transplantation. Gen Thorac Cardiovasc Surg 2021; 69:625–630.
Cypel M, Yeung JC, Liu M, et al. Normothermic ex vivo lung perfusion in clinical lung transplantation. N Engl J Med 2011; 364:1431–1440.
Sanchez PG, Davis RD, D’Ovidio F, et al. The NOVEL Lung Trial one-year outcomes. J Heart Lung Transplant 2014; 33:S71–S72.
Warnecke G, Van Raemdonck D, Smith MA, et al. Normothermic ex-vivo preservation with the portable Organ Care System Lung device for bilateral lung transplantation (INSPIRE): a randomised, open-label, noninferiority, phase 3 study. Lancet Respir Med 2018; 6:357–367.
Slama A, Schillab L, Barta M, et al. Standard donor lung procurement with normothermic ex vivo lung perfusion: a prospective randomized clinical trial. J Heart Lung Transplant 2017; 36:744–753.
Loor G, Warnecke G, Villavicencio MA, et al. Portable normothermic ex-vivo lung perfusion, ventilation, and functional assessment with the Organ Care System on donor lung use for transplantation from extended-criteria donors (EXPAND): a single-arm, pivotal trial. Lancet Respir Med 2019; 7:975–984.
Nilsson T, Wallinder A, Henriksen I, et al. Lung transplantation after ex vivo lung perfusion in two Scandinavian centres. Eur J Cardiothorac Surg 2019; 55:766–772.
Fisher A, Andreasson A, Chrysos A, et al. An observational study of Donor Ex Vivo Lung Perfusion in UK lung transplantation: DEVELOP-UK. Health Technol Assess 2016; 20:1–276.
Tikkanen JM, Cypel M, Machuca TN, et al. Functional outcomes and quality of life after normothermic ex vivo lung perfusion lung transplantation. J Heart Lung Transplant 2015; 34:547–556.
Koch A, Pizanis N, Olbertz C, et al. One-year experience with ex vivo lung perfusion: preliminary results from a single center. Int J Artif Organs 2018; 41:460–466.
Wallinder A, Riise GC, Ricksten SE, et al. Transplantation after ex vivo lung perfusion: a midterm follow-up. J Heart Lung Transplant 2016; 35:1303–1310.
Fildes JE, Archer LD, Blaikley J, et al. Clinical outcome of patients transplanted with marginal donor lungs via ex vivo lung perfusion compared to standard lung transplantation. Transplantation 2015; 99:1078–1083.
Divithotawela C, Cypel M, Martinu T, et al. Long-term outcomes of lung transplant with ex vivo lung perfusion. JAMA Surg 2019; 154:1143–1150.
Emaminia A, Lapar DJ, Zhao Y, et al. Adenosine A2A agonist improves lung function during ex vivo lung perfusion. Ann Thorac Surg 2011; 92:1840–1846.
National Heart Lung and Blood Institute (NHLBI). A Randomized, Blinded, Multisite, Pilot Study to Evaluate Adenosine 2A Receptor Agonist (REGADENOSON) in the Rehabilitation of Marginal Donor Lungs. ClinicalTrials.gov Identifier: NCT04521569 2020.
Martens A, Boada M, Vanaudenaerde BM, et al. Steroids can reduce warm ischemic reperfusion injury in a porcine donation after circulatory death model with ex vivo lung perfusion evaluation. Transpl Int 2016; 29:1237–1246.
Hameed AM, Lu DB, Burns H, et al. Pharmacologic targeting of renal ischemia-reperfusion injury using a normothermic machine perfusion platform. Sci Rep 2020; 10:6930.
Bishawi M, Roan JN, Milano CA, et al. A normothermic ex vivo organ perfusion delivery method for cardiac transplantation gene therapy. Sci Rep 2019; 9:8029.
Machuca TN, Cypel M, Bonato R, et al. Safety and efficacy of ex vivo donor lung adenoviral IL-10 gene therapy in a large animal lung transplant survival model. Hum Gene Ther 2017; 28:757–765.
Zhang X, Zheng X, Sun H, et al. Prevention of renal ischemic injury by silencing the expression of renal caspase 3 and caspase 8. Transplantation 2006; 82:1728–1732.
Figueiredo C, Carvalho Oliveira M, Chen-Wacker C, et al. Immunoengineering of the vascular endothelium to silence MHC expression during normothermic ex vivo lung perfusion. Hum Gene Ther 2019; 30:485–496.
Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol 2015; 33:941–951.
Cheng Z, Al Zaki A, Hui JZ, et al. Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science 2012; 338:903–910.
Cui J, Qin L, Zhang J, et al. Ex vivo pretreatment of human vessels with siRNA nanoparticles provides protein silencing in endothelial cells. Nat Commun 2017; 8:191.
Khalifé-Hocquemiller T, Sage E, Dorfmuller P, et al. Exogenous surfactant attenuates lung injury from gastric-acid aspiration during ex vivo reconditioning in pigs. Transplantation 2014; 97:413–418.
Nakajima D, Liu M, Ohsumi A, et al. Lung lavage and surfactant replacement during ex vivo lung perfusion for treatment of gastric acid aspiration-induced donor lung injury. J Heart Lung Transplant 2017; 36:577–585.
Machuca TN, Hsin MK, Ott HC, et al. Injury-specific ex vivo treatment of the donor lung: pulmonary thrombolysis followed by successful lung transplantation. Am J Respir Crit Care Med 2013; 188:878–880.
Nakajima D, Cypel M, Bonato R, et al. Ex vivo perfusion treatment of infection in human donor lungs. Am J Transplant 2016; 16:1229–1237.
Andreasson A, Karamanou DM, Perry JD, et al. The effect of ex vivo lung perfusion on microbial load in human donor lungs. J Heart Lung Transplant 2014; 33:910–916.
Zinne N, Krueger M, Hoeltig D, et al. Treatment of infected lungs by ex vivo perfusion with high dose antibiotics and autotransplantation: a pilot study in pigs. PLoS One 2018; 13:e0193168.
Ribeiro RVP, Ku T, Wang A, et al. Ex vivo treatment of cytomegalovirus in human donor lungs using a novel chemokine-based immunotoxin. J Heart Lung Transplant 2022; 41:287–297.
Duncan AJ, Dummer JS, Paradis IL, et al. Cytomegalovirus infection and survival in lung transplant recipients. J Heart Lung Transplant 1991; 10 (5 pt 1):638–644.
Kirklin JK, Naftel DC, Levine TB, et al. Cytomegalovirus after heart transplantation. Risk factors for infection and death: a multiinstitutional study. The Cardiac Transplant Research Database Group. J Heart Lung Transplant 1994; 13:394–404.
Mordant P, Nakajima D, Kalaf R, et al. Mesenchymal stem cell treatment is associated with decreased perfusate concentration of interleukin-8 during ex vivo perfusion of donor lungs after 18-h preservation. J Heart Lung Transplant 2016; 35:1245–1254.
Nakajima D, Watanabe Y, Ohsumi A, et al. Mesenchymal stromal cell therapy during ex vivo lung perfusion ameliorates ischemia-reperfusion injury in lung transplantation. J Heart Lung Transplant 2019; 38:1214–1223.
Martens A, Ordies S, Vanaudenaerde BM, et al. Immunoregulatory effects of multipotent adult progenitor cells in a porcine ex vivo lung perfusion model. Stem Cell Res Ther 2017; 8:159.
Lonati C, Bassani GA, Brambilla D, et al. Mesenchymal stem cell-derived extracellular vesicles improve the molecular phenotype of isolated rat lungs during ischemia/reperfusion injury. J Heart Lung Transplant 2019; 38:1306–1316.
Stone ML, Zhao Y, Robert Smith J, et al. Mesenchymal stromal cell-derived extracellular vesicles attenuate lung ischemia-reperfusion injury and enhance reconditioning of donor lungs after circulatory death. Respir Res 2017; 18:212.
McAuley DF, Curley GF, Hamid UI, et al. Clinical grade allogeneic human mesenchymal stem cells restore alveolar fluid clearance in human lungs rejected for transplantation. Am J Physiol Lung Cell Mol Physiol 2014; 306:L809–815.
Hatami S, White CW, Shan S, et al. Myocardial functional decline during prolonged ex situ heart perfusion. Ann Thorac Surg 2019; 108:499–507.
McLeod JS, Poling C, Church JT, et al. Ex vivo heart perfusion for 72 hours using plasma cross circulation. Asaio j 2020; 66:753–759.
Hsin MKY, Iskender I, Nakajima D, et al. Extension of donor lung preservation with hypothermic storage after normothermic ex vivo lung perfusion. J Heart Lung Transplant 2016; 35:130–136.
Roszkowska A, Tascon M, Bojko B, et al. Equilibrium ex vivo calibration of homogenized tissue for in vivo SPME quantitation of doxorubicin in lung tissue. Talanta 2018; 183:304–310.
Ebbesen M, Jensen TG, Andersen S, Pedersen FS. Ethical perspectives on RNA interference therapeutics. Int J Med Sci 2008; 5:159–168.
Damase TR, Sukhovershin R, Boada C, et al. The limitless future of RNA therapeutics. Front Bioeng Biotechnol 2021; 9:628137.